.jpg "/Content/Upload/Product/Human_ELISA_kits_Diagnocine_1200_1200(31).jpg")
Human insulin-like growth factors binding protein 2,IGFBP-2 ELISA Kit
The Ultimate 1-Stop ELISA Marketplace:
60,000+ ELISA kits Available to Serve Scientists from All Fields of Life Science
Always Powered by Diagnocine for Precision Research.
Most comprehensive buffers, reagents and detection agents are provided with each kit to optimize data output.
All-inclusive format covers everything from sample preparation to signal detection. Every step can be customized and optimized for your precision research.
DiagnoCine Precision buffers and reagents are Made in USA ISO 13485 Certified
Why waste time searching for your ELISA kit when you can get everything in one place? Diagnocine can provide you with all the ELISA needs you have (customized ELISAs also available) on the planet through a single, streamlined ordering process.
* all types of species
* HRP and AP detection
* Low target signal enhancement
* Inquire about a trial version or a customized version
4 core reagents below are included with every order, plus 1 of the 2 detection-specific reagents (matched automatically to your kit type) — 5 components, every time.
+ the 5th component, matched to your kit's detection method:
If you have any questions or need additional information, please call us at 551-245-1033 or email us at support@diagnocine.com. Our team will be happy to assist you.
Universal Compatibility
All buffers and detection reagents work seamlessly across target proteins, bridging the gap in assay consistency.
1-Stop Convenience
Consolidate your lab's purchasing. Source all ELISA needs and experience optimal buffers and reagents in a single shipment.
Enhanced Precision
Designed by scientists for scientists, all components are engineered to deliver sharper results and an optical signal.
Human insulin-like growth factors binding protein 2,IGFBP-2 ELISA Kit
Sandwich quantitative immunoassay for insulin-like growth factor binding protein 2, 36kDa in human serum, plasma, tissue homogenates available in multiple catalog sizes:
Note: Please send inquiries regarding Trial 24T orders to support@diagnocine.com.
| Target name | insulin-like growth factor binding protein 2, 36kDa |
| Uniprot No. | P18065 |
| Species | Homo sapiens (Human) |
| Sample types | serum, plasma, tissue homogenates |
| Detection range | 0.78 ng/mL-50 ng/mL |
| Sensitivity | 0.195 ng/mL |
| Assay time | 1-5h |
| Sample loading volume | 50-100μL |
| Detection wavelength | 450 nm |
| Assay principle | Sandwich (Quantitative) |
| Data analysis | Standard curve + Curve Expert software |
| Research area | Signal Transduction |
| Storage condition | 2-8°C (see protocol for full details) |
| Shipping condition | 4 °C |
| Shelf life | 6 months |
10 business days
Processing + 3-5 days shipping
In Stock : USA
Worldwide shipping available
Antibody capture
450 nm detection
Standard curve
Quantification
In this sandwich ELISA, insulin-like growth factor binding protein 2, 36kDa in the sample is captured between a pre-coated capture antibody and a detection antibody. Signal intensity is proportional to analyte concentration. Quantification uses a standard curve fitted with Curve Expert software, covering 0.78 ng/mL-50 ng/mL with a minimum detectable dose of 0.195 ng/mL.
The product CSB-E04588h is a sandwich ELISA kit developed to measure concentrations of human IGFBP2 in serum, plasma, or tissue homogenates. This assay uses the sandwich enzyme immunoassay technique in combination with the enzyme-substrate chromogenic reaction to quantify the analyte in the sample. The color develops positively to the amount of IGFBP2 in samples. The color intensity is measured at 450 nm via a microplate reader.
IGFBP2 is considered a major regulator of IGFs bioavailability in the metabolic signaling pathway and controls the distribution, function, and activity of IGFs in the pericellular space. It is a developmentally regulated gene that is highly expressed in embryonic and fetal tissues and markedly decreases after birth. Abnormal overexpression of IGFBP2 is related to an aggressive phenotype of a broad range of human cancers, including glioma, ovarian, prostate, pancreatic, breast, lung, colorectal, melanoma, and liver cancer. High circulating IGFBP2 levels may serve as a useful diagnostic or prognostic tumor biomarker in many types of cancer and are closely linked to relapse and a poorer outlook for patients with cancer.
- IGFBP-2 overexpression in HUVECs promoted endothelial progenitor cells(EPC)-endothelial adhesion. The RGD motif in its C-domain is required for interaction with integrin alpha5beta1. PMID: 26076738
- The expression levels of maspin were lower in the cisplatin-resistant tissue and cells, and was enhanced by IGFBP-2 inhibition. PMID: 26080829
- These results implicate TRIB3 and IGFBP2, both of which are known to be overexpressed in several types of cancers, as pro-survival modulators of cell viability in nutrient-deficient microenvironments. PMID: 26094770
- Data show that modulation of insulin like growth factor binding protein 2 (IGFBP2) expression affects proliferation, motility, and chemosensitization of eophageal adenocarcinoma (EAC) cells in a serum-dependent manner. PMID: 26317790
- Insulin-like growth factor binding protein 2 is strongly associated with restoration of keratocyte phenotype in HCFs. PMID: 26559475
- Serum IGFBP2 reflects disease activity and renal pathology changes in lupus nephritis. PMID: 26616478
- Insulin-like growth factor binding protein 2 potentiates glioblastoma tumor growth by the activation of the beta-catenin pathway through its C-terminal domain, and their coexpression possibly contributes to worse patient prognosis. PMID: 27044294
- Co-ordinated and reciprocal alteration in IGFBP-2 and -5 expression may play a role in the acquisition of endocrine resistance in breast cancer. PMID: 27050076
- IGFBP2 and SOCS3 were up-regulated in Kashin-Beck disease chondrocytes and decreased with increasing selenium concentrations. IGFBP2 expressed highest in the middle zone of KBD cartilage, SOCS3 expressed higher in the middle and deep zone. IGFBP2 and SOCS3 may be the biomarkers for KBD diagnosis and evaluating the effect of selenium supplement. PMID: 27099071
- The monoclonal gammopathy of undetermined significance and multiple myeloma patients displayed a significant increase in intact IGFBP-2 and decrease in intact IGFBP-3 in the circulation compared to control individuals. PMID: 27111220
- In human whole blood cells, methylation of IGFBP2 at the homologous CpG site was increased in obese men with impaired glucose tolerance. In conclusion, our data show that increased methylation of hepatic Igfbp2 during infancy predicts the development of fatty liver later in life and is linked to deterioration of glucose metabolism. PMID: 27126637
- In patients with malignant and borderline ovarian tumors, the level of IGFBP-2 was higher than in healthy women and in patients with benign ovarian tumors. PMID: 27165066
- Together, this study validated that T-2 toxin exposure might promote the progression of KBD by inducing chondrocyte injury, suppressing matrix synthesis and accelerating cellular catabolism through IGFBP2. Therefore, this research will elucidate a new insight about how T-2 toxin participate in the pathogenesis of KBD. PMID: 27416762
- IGFBP2 and IGFBP3 may serve as compensatory biomarkers for CA19-9. Early diagnosis with this marker combination may improve the prognosis of invasive ductal adenocarcinoma of pancreas patients. PMID: 27579675
- patients with low IGFBP2 expressiondisplay a clear advantage in overall and disease-free survival, whereas those with high IGFBP2 expressionhave worse median survival than IDH-wildtype patients. PMID: 27852048
- Data suggest that circulating insulin-like growth factor-binding protein 2 (IGFBP2) has potential as a biomarker predicting prognosis for gastric cancer patients. PMID: 28036255
- The interaction of IGFBP2 and p63 might account for the pathogenesis of rhabdomyosarcoma tumors. PMID: 28129571
- IGFBP2 protein levels are altered in type 2 diabetes mellitus patients and associated with cardiovascular disease risk factors. PMID: 28179448
- We verified that NFIA binds to the IGFBP2 promoter and transcriptionally enhances IGFBP2 expression levels. We identified that NFIA-mediated IGFBP2 signaling pathways are involved in miR-302b-induced glioma cell death. PMID: 28323865
- these results suggest that IGFBP2 plays an important role in promoting tumorigenesis, through estrogen and ERalpha signaling pathway. PMID: 28410230
- The associated effects appear to be mediated by inhibition of IGFBP-2 expression and stimulation of p21 expression. This suggests that simulated microgravity might represent a promising method to discover new targets for glioma therapeutic strategy. PMID: 28707224
- mechanistic investigations defined insulin-like growth factor binding protein 2 (IGFBP2)as a direct and functional downstream target of microRNA-592, which was involved in the microRNA-592-mediated tumor-suppressive effects in glioma cells. PMID: 28718372
- IGFBP2 overexpression increased the expression of p-p65 and nuclear p65, while IGFBP2 knockdown reduced the expression of p-p65 and nuclear p65. PMID: 29228449
- Following IGFBP2 knockdown using rAAV2-ZsGreen-shRNA-hIGFBP2, matrix metalloproteinase2 expression was significantly reduced in tumor tissues compared with that in rAAV2ZsGreenshRNAscramble treated tumor tissues. PMID: 29344663
| Intra-assay Precision (Precision within an assay): CV%<8% | ||||||
| Three samples of known concentration were tested twenty times on one plate to assess. | ||||||
| Inter-assay Precision (Precision between assays): CV%<10% | ||||||
| Three samples of known concentration were tested in twenty assays to assess. | ||||||
| These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| To assess the linearity of the assay, samples were spiked with high concentrations of human IGFBP-2 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. | ||||||
| Sample | Serum(n=4) | |||||
| 1:5 | Average % | 97 | ||||
| Range % | 91-105 | |||||
| 1:10 | Average % | 95 | ||||
| Range % | 92-98 | |||||
| 1:20 | Average % | 92 | ||||
| Range % | 86-99 | |||||
| 1:40 | Average % | 94 | ||||
| Range % | 89-100 | |||||
| The recovery of human IGFBP-2 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. | ||||||
| Sample Type | Average % Recovery | Range | ||||
| Serum (n=5) | 96 | 89-101 | ||||
| EDTA plasma (n=4) | 94 | 88-99 | ||||
